KPV is a tripeptide — three amino acids, lysine-proline-valine — that corresponds to the C-terminal fragment of alpha-MSH, a hormone the body makes. Its anti-inflammatory activity has been characterised in laboratory and animal work: it dampens NF-κB and MAP-kinase signalling, lowers pro-inflammatory cytokines, and is carried into cells by the PepT1 transporter. The published evidence is preclinical — cell lines and mouse models — and it is not approved by any regulator, for any use, anywhere.
By Tessaro Pty Ltd, the maker of Pepti · Last reviewed
This page is a reference, not a protocol. It sets out what the published research reports and in which model systems, what the absence of a human half-life means for a record, and what a clean log holds. It gives no dose figures and no schedule, and the section below explains why that is deliberate rather than an omission.
| Property | Value |
|---|---|
| Class / type | Tripeptide (Lys-Pro-Val); the C-terminal fragment of alpha-MSH — (Dalmasso et al., 2008; Brzoska et al., 2008) |
| Evidence base | Preclinical only — human intestinal cell lines and mouse colitis models (animal and in-vitro); no human efficacy trials — (Dalmasso et al., 2008; Gravina et al., 2023) |
| Half-life | No reliable human half-life has been published |
| Regulatory status | Not approved by any regulator, in any jurisdiction, for any indication |
The foundational study is an animal-and-cell one. In human intestinal epithelial cell lines and in mouse models of colitis, Dalmasso and colleagues reported that “KPV is a tripeptide (Lys-Pro-Val), which possesses anti-inflammatory properties”: nanomolar concentrations inhibit NF-κB and MAP-kinase signalling and reduce pro-inflammatory cytokine secretion, and the peptide is carried into cells by PepT1, a transporter on intestinal and immune cells (Dalmasso et al., Gastroenterology, 2008). Oral KPV reduced chemically induced (DSS- and TNBS-induced) colitis in mice. Every one of those results comes from a cell line or a mouse, not from a person.
Reviews place KPV in context. Because it keeps the anti-inflammatory activity of alpha-MSH but not the pigment action of the parent hormone, the C-terminal tripeptide has been described as a candidate worth pursuing, with effects reported across in-vitro and in-vivo (animal) models (Brzoska et al., Endocrine Reviews, 2008). A review of the wider melanocortin system makes the same methodological point: the encouraging inflammatory-bowel-disease findings have accumulated in mouse models of colitis (Gravina et al., Cells, 2023).
The limits are the whole story here. This is a preclinical evidence base: no published human efficacy trial, no approved indication, and no regulator anywhere that has cleared KPV for use. Results obtained in a dish or a mouse are a reason to run human studies, not a substitute for them.
No reliable human half-life has been published. No human pharmacokinetic study has characterised how quickly KPV is cleared, so there is no authorised number to quote. The practical consequence for a record is simple: you cannot lean on a known clearance curve to tell you where levels sit between entries, so the dated log of what you entered and when is the only timeline you can rely on.
That is also why Pepti does not print a half-life for this compound. Where a figure exists from a human study, the app can use it; where none does, as here, the half-life view is driven entirely by a value you enter yourself. The number is yours to supply or to leave blank — the app will not invent one and present it as settled.
This is general handling, not product-specific instruction. Peptides degrade by both chemical and physical routes, and formulations are stabilised differently in aqueous solution than in the dried (lyophilized) state (Manning et al., Pharmaceutical Research, 2010). Material supplied as a dried powder is generally the more robust form and is inert until a diluent is added; once in solution it is more vulnerable, so it is kept cold and dark, used within a limited window, protected from repeated freeze-thaw, and handled with clean technique.
The record-keeping point is the one Pepti cares about: the moment a powder becomes a solution, two facts are created that you will need later and will not otherwise remember — the diluent volume you added and the resulting concentration. Writing them down at the time is the difference between a vial you can still measure from accurately and one you are guessing about.
Pepti is built for exactly this situation: a compound you already have a figure for, supplied in a form that needs measuring. The reconstitution calculator takes the variables you enter — the amount in the vial and the diluent volume — and returns the concentration and the draw volume for the figure you already hold. Every input is a value you supply; none is a dose the app suggests.
From there the injection-site rotation tracker keeps a 12-site sequence so each administration lands somewhere other than the last, and the half-life view — because no human half-life exists for this compound — is driven entirely by a value you choose to enter. The app holds the arithmetic and the history; the clinical figures stay with you.
KPV is a research peptide. There is no approved label anywhere, so there is no authorised dose, no approved titration path, and no clinician-facing guidance for it. Any figure published as a “typical dose” for an unapproved compound is not drawn from an approved source, because none exists — it comes from forum consensus, vendor copy, or someone extrapolating a number out of an animal study that was never designed to set a human dose.
Pepti is a measurement and record-keeping tool. It converts a figure you already have into a draw volume and syringe units, tracks what is left in each vial, and remembers where the last injection went — but it does not supply the figure, for this compound or any other. Pages that publish dose tables for preclinical compounds are publishing folklore with the typography of evidence: the numbers look authoritative because they are set in a table, not because anything stands behind them. The figure belongs to you and whoever directs your use; the arithmetic is what we are for.
Because there is no settled schedule for this compound, the thing that makes a record useful is not cadence but completeness: each entry should say enough that the next one, and your reading of the trend months later, is unambiguous.
The reconstitution calculator converts the figures you already have into a draw volume and a count of doses per vial, and a peptide tracker app keeps those entries, the site sequence and your notes on one timeline.
KPV is a tripeptide, three amino acids in sequence (lysine-proline-valine), that corresponds to the C-terminal fragment of alpha-MSH, a hormone the body makes. In laboratory and animal studies it has shown anti-inflammatory activity, and it is carried into cells by the PepT1 transporter. It is a research peptide, not an approved medicine.
No. KPV is not approved by any regulator, in any country, for any indication. The published work on it is preclinical, meaning cell-culture and animal studies rather than completed human trials, so there is no label, no authorised dosing, and no clinician-facing guidance for it.
In human intestinal cell lines and in mouse models of colitis, KPV reduced inflammatory signalling (NF-kB and MAP kinase) and lowered pro-inflammatory cytokines, with its uptake into cells mediated by the PepT1 transporter (Dalmasso et al., Gastroenterology 2008). Reviews describe it as the anti-inflammatory C-terminal fragment of alpha-MSH that lacks the pigment action of the parent hormone (Brzoska et al., Endocrine Reviews 2008). This evidence is from cell and animal models, not human efficacy trials.
No reliable human half-life has been published. No human pharmacokinetic study has characterised one, so any single number quoted for it is not drawn from a human study. Pepti's half-life tool works from a value you enter yourself, never one we supply.
It depends on the form. Research material is commonly supplied as a lyophilized powder, which is inert until a diluent is added, while some material is supplied already in solution. These are two different physical products, and a record that does not say which one it describes becomes ambiguous later.
No. Pepti supplies no dose figures for KPV or for anything else. It records the figure you already have from whoever directs your use, converts it into a draw volume and syringe units, tracks what is left in each vial, and keeps the site sequence. The arithmetic is ours; the figure is not.
This page is a reference on published evidence and record-keeping. It does not recommend KPV or any other substance, and it provides no dose figure, no titration amount, and no schedule. KPV is a research peptide and is not approved for any use.
The Pepti peptide tracker for iPhone keeps the log, the site sequence, the vial count and your notes in one place.
Not medical advice. Pepti is a record-keeping and measurement tool, not a medical device.
Get Pepti on the App Store